SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, controlled trial to prove efficacy of S-1 and Oxaliplatin
as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients who undergo D2 gastrectomy.
The primary endpoint is three-year free disease and the second primary includes five-year
overall survival, safety and R0 resection rate.